Pipilas Alexandra, Martyn Trejeeve, Lindenfeld JoAnn
Department of Cardiovascular Medicine, Boston University, Boston, Massachusetts, USA.
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Struct Heart. 2022 Oct 22;6(6):100082. doi: 10.1016/j.shj.2022.100082. eCollection 2022 Nov.
Medical therapy for heart failure (HF) has expanded rapidly in the last decade contributing to improved morbidity and mortality for patients living with HF. The indicated treatments have been traditionally stratified based on left ventricular ejection fraction. The optimization of HF medical therapy is important for interventional and structural cardiologists as HF remains among the most common causes of periprocedural hospitalization and death. Additionally, optimization of medical therapy for HF prior to the utilization of device-based therapies as well as enrollment in clinical trials is crucial. This review will serve to highlight medical therapy indicated across the left ventricular ejection fraction strata.
在过去十年中,心力衰竭(HF)的药物治疗迅速发展,有助于改善HF患者的发病率和死亡率。传统上,已根据左心室射血分数对指定治疗进行分层。HF药物治疗的优化对于介入心脏病学家和心脏结构病学家而言非常重要,因为HF仍然是围手术期住院和死亡的最常见原因之一。此外,在使用基于器械的治疗以及参加临床试验之前,优化HF药物治疗至关重要。本综述将着重介绍适用于不同左心室射血分数分层的药物治疗。